Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Trimmed by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 154,581 shares of the life sciences company’s stock after selling 42,719 shares during the period. Exchange Traded Concepts LLC owned 0.10% of Illumina worth $20,159,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Trivant Custom Portfolio Group LLC boosted its position in shares of Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after buying an additional 125 shares during the period. Versant Capital Management Inc boosted its stake in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the period. Industrial Alliance Investment Management Inc. purchased a new position in shares of Illumina during the second quarter valued at $34,000. Massmutual Trust Co. FSB ADV grew its stake in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in Illumina during the fourth quarter valued at approximately $56,000. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ILMN. UBS Group upped their target price on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. cut their price target on Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Daiwa Capital Markets upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their target price for the company from $120.00 to $154.00 in a research note on Friday, August 16th. Citigroup lifted their price target on shares of Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 10th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $150.05.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $145.54 on Friday. The business has a 50-day moving average price of $130.19 and a two-hundred day moving average price of $120.76. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $148.19. The stock has a market capitalization of $23.18 billion, a P/E ratio of -7.60 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the business posted $0.32 EPS. The firm’s revenue was down 5.4% compared to the same quarter last year. Equities analysts predict that Illumina, Inc. will post 3.63 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.